TrialClinical and translational medicine2022

Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.

Anne Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.